All In Biotech

Drug Trial Radar · NCT04408625

Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)

A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of LY3884963 in Patients With Fronto-Temporal Dementia With Progranulin Mutations (FTD-GRN)

Last checked: Nov 19, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

35

Planned (sponsor's estimate)

Start

Nov 9, 2020

Primary completion

Nov 30, 2029

Study completion Nov 30, 2029

Sponsor

Lead sponsor
Prevail TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Eli Lilly and Company
First posted
May 29, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study J4B-MC-OKAA is a Phase 1/2, multi-center, open-label ascending dose, first-in-human study that will evaluate the safety and effect of intra-cisternal LY3884963 administration on progranulin protein (PGRN) levels in patients with frontotemporal dementia with progranulin mutations (FTD-GRN). Two escalating dose (low dose and medium dose) cohorts are planned, as well as one bridging cohort which will allocate patients to receive either low or medium dose. The duration of the study is 5 years. During the first year, patients will be evaluated for the effect of LY3884963 on safety, tolerability, immunogenicity, biomarkers, and efficacy. Patients will follow up for an additional 4 years to monitor safety and changes on selected biomarkers and clinical outcomes.

Conditions

  • Frontotemporal Dementia

Interventions

  • LY3884963Biological

    Participants will receive a single dose of LY3884963, administered intra cisterna magna

  • MethylprednisoloneDrug

    IV pulses every 2 weeks in the first 3 months.

  • Optional SirolimusDrug

    At the investigators discretion following steroid tolerability issues, patients may receive a loading dose, followed by maintenance dose, followed by dose tapering; administered as concomitant medication

  • Optional PrednisoneDrug

    If needed and at the investigator discretion, Oral Prednisone may be added to the immunosuppression regimen

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events Leading to discontinuationTime frame: 5 Years
  2. Sum of adverse reactions (ARs) and suspected ARsTime frame: 5 years
  3. Sum of serious ARs and serious suspected ARsTime frame: 5 years
  4. Incidence of procedure or treatment-emergent AEsTime frame: 5 years
  5. Change in AAV9, PGRN, and NfL immunogenicity in bloodTime frame: Days 7, 14, and 21 and at Months 1, 1.5, 2, 3, 6, 9, 12, 18, and 24
  6. Change in AAV9, PGRN, and NfL immunogenicity in CSFTime frame: Months 2, 6, 12, 18, and 24
  7. Change in PGRN levels in bloodTime frame: Days 7, 14, and 21 and at Months 1, 1.5, 2, 3, 6, 9, 12, 18, and 24
  8. Change in PGRN levels in CSFTime frame: Months 2, 6, 12, 18, and 24

Locations

12 sites in 6 countries. Site status is shown where the registry gives one.

  • k2 Medical Research-Maitland

    Maitland, Florida

  • PPD Phase 1 Clinic, 100 West Gore Street, Suite 202

    Orlando, Florida

  • Lahey Hospital & Medical Center, 41 Burlington Mall Road

    Burlington, Massachusetts

  • Hospital of the University of Pennsylvania, 3 West Gates Building, 3400 Spruce Street

    Philadelphia, Pennsylvania

  • Royal Prince Alfred Hospital, Brain & Mind Research Institute, 94 Mallet Street

    Camperdown, New South Wales, Australia

  • UZ Leuven, Neurologie Herestraat 49

    Leuven, Belgium

  • Centre Mémoire de Ressources

    Lille, France

  • Le Ber, Institut du Cerveau et de la Moelle Epinière

    Paris, France

  • AP-HM Hôpital de La Timone

    Saint-Pierre, Marseille, France

  • Hospital Clinic de Barcelona, Villaroel 170 Servicio de Neurología

    Barcelona, Spain

  • Hospital Universitario de Donostia, Servicio De Neurologia, Consultas Externas Neurologia, San Sebastian, Guipúzcoa

    Donostia / San Sebastian, Spain

  • University College London,Queen Square, Dementia Research Building, London,

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.